Seven emerging AI healthcare technologies have been selected for the second phase of the MHRA’s AI Airlock programme.
Similar Posts
Five festive mistakes you didn’t know you were making: MHRA urges the public to be merry, not risky – don’t mix medicines with alcohol
This holiday season, the MHRA is highlighting one of the most overlooked winter health risks: combining medicines with alcohol.
MHRA Safety Roundup: September 2025
Summary of the latest safety advice for medicines and medical device users
Statutory guidance: MHRA fees
Fees payable to the MHRA from 2025.
Medicines and Medical Devices Act 2021 – Stakeholder survey
We invite feedback on the operation and impact of the human medicines and medical devices legislation as part of a statutory review required under the Medicines and Medical Devices Act 2021.
Consultation on the International Council for Harmonisation Guideline E20 for adaptive clinical trial design
The MHRA is consulting with UK stakeholders to gather feedback and comments on ICH E20, a new international guideline.
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause.